Events

Click here to see a list of our past events. 

   

Nov
17
11:00am - 12:00pm Virtual

Everything you need to know before applying for SBIR/STTR startup funding!

On Tuesday, November 17 at 11 a.m. ET, Kirk Macolini of InteliSpark will lead a free virtual workshop on the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) application process. Join us to learn how to secure non-dilutive funding for your startup.

You will learn:

  • How to craft a successful SBIR/STTR application
  • Strategies for developing a competitive proposal
  • The latest news about the SBIR/STTR program

Register here. 

Two people's hands pointing at the screen of a tablet computer
Nov
18
5:30pm - 7:30pm BioVenture eLab Makerspace (1157 York Ave, New York, NY)

Join us at the BioVenture eLab Makerspace for a hands-on 3D Printing Seminar!

Do you have ideas for a new medical device or a tool to enhance your medical instruction? This program is for you!

Visit the BioVenture eLab Makerspace to learn how to use specialized software to create designs for 3D printing and bring your innovations to life. Topics covered in this seminar will include:

  • biodesign concepts
  • how to use design software
  • tips for using a 3D printer to generate an initial prototype.

The seminar will feature Dylan Manuele, a Weill Cornell Medicine medical student who possesses a biomedical engineering degree from the University of Rochester. Dylan serves as vice president of Weill Cornell Class Council and Junior Clinician, Weill Cornell Community Clinic.

Register here. 

A 3D printer printing a small prototype with circular holes
Nov
25
5:00am - 10:15am Virtual

Oral delivery of macromolecules such as peptides and proteins remains one of the major challenges in drug delivery. Despite considerable advances, barriers including gastrointestinal degradation, limited permeability, food effects and exposure variability continue to limit broader adoption of oral macromolecules.

Successful oral delivery of macromolecules has the potential to improve the treatment experience for patients, reduce reliance on injection- based administration pathways, and broaden access to therapies.

As the field matures, the focus is increasingly shifting from whether oral delivery can work to understanding which approaches are most likely to translate into robust, scalable and commercially viable medicines. No single technology is likely to address all barriers associated with oral delivery of macromolecules. Progress may depend on combining complementary approaches, with distinct technologies addressing different aspects of the challenge, including gastrointestinal stability, permeability, food effects, exposure variability and manufacturability. As a result, collaboration across academia, biotechnology companies, technology developers and pharmaceutical R&D organizations remains critical.

Johnson & Johnson invites external innovators, academic leaders, entrepreneurs, investors and ecosystem partners to a hybrid scientific engagement event in the Netherlands focused on device- and formulation-based technologies for oral delivery of macromolecules.

*This event will be in-person in the Netherlands with a virtual broadcast for remote participants. 

Register here. 

X ray image of teeth
Dec
03
2:00pm - 3:30pm

What does it take to transform a scientific discovery into a lifesaving therapeutic?

Join us on Thursday, December 3, from 2:00–3:30 p.m. ET, for a special fireside chat with Barry S. Coller, MD, a pioneer in cardiovascular medicine whose groundbreaking research in antiplatelet therapies has helped shape clinical practice and contributed to the formation of several biotechnology companies, including Accumetrics and CeleCor.

Dr. Coller will share insights from his remarkable journey spanning scientific discovery, drug development and entrepreneurship, including the challenges and opportunities of translating academic innovations into therapies that benefit patients.

The conversation will be moderated by Daniel Bloomfield, MD, Partner at Ascenta Capital, former Merck SVP Clinical Development, and biotech CEO and CMO.

RSVP here. 

 

Headshots of two Caucasian men wearing glasses and with gray hair
Dec
10
5:30pm - 8:00pm Uris Auditorium, 1300 York Ave, New York, NY 10065

Join us as our finalist teams from the Accelerating BioVenture Innovation (ABI) course pitch their technologies to early-stage investor judges.

Accelerating BioVenture Innovation (ABI) is a 15-week course in entrepreneurship training that builds teams around patented technologies from Weill Cornell, Memorial Sloan Kettering, and Rockefeller University. The program educates participants on all aspects of launching a company. Teams create pitch decks after weeks of instruction and mentorship from industry experts, and then finalist teams are selected to pitch to a panel of investor judges.

A networking reception will follow.

Register here. 

An auditorium filled with people